Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: A randomized, double-blind study

Table 2 Absolute and relative changes from baseline in the irritable bowel syndrome severity score referring to irritable bowel syndrome type (mean ± SD)

	Placebo (n = 25 )		LCR35 (n = 25)
	Absolute changes	Relative changes (%)	Absolute changes	Relative changes (%)
IBS with predominance of constipation	n = 7		n = 4
Post-treatment (V3-V2)	-109.4 ± 93.1	-41.0 ± 32.7	-56.8 ± 43.9	-20.5 ± 16.5
End of study (V4-V2)	-61.0 ± 96.0	-23.5 ± 35.0	-27.5 ± 31.6	-10.1 ± 11.3
IBS with predominance of diarrhoea	n = 8		n = 7
Post-treatment (V3-V2)	-1.9 ± 82.8	-3.1 ± 35.6	-105.0 ± 128.4	-36.6 ± 44.7
End of study (V4-V2)	23.9 ± 119.7	4.9 ± 46.8	-54.9 ± 151.7	-19.1 ± 53.5
Mixed IBS	n = 6		n = 11
Post-treatment (V3-V2)	-70.0 ± 91.4	-31.2 ± 38.8	-50.3 ± 99.4	-21.8 ± 39.7
End of study (V4-V2)	-68.3 ± 110.6	-30.7 ± 50.1	-53.3 ± 97.4	-20.5 ± 39.9
Unsubtyped IBS	n = 4		n = 3
Post-treatment (V3-V2)	-101.8 ± 96.2	-46.7 ± 46.7	-22.0 ± 99.9	-17.4 ± 45.9
End of study (V4-V2)	-63.8 ± 97.7	-31.3 ± 50.8	21.3 ± 140.8	4.3 ± 51.0

IBS: Irritable bowel syndrome.